271 related articles for article (PubMed ID: 35311069)
1. Prognostic Implications of Molecular Subtypes in Primary Small Cell Lung Cancer and Their Correlation With Cancer Immunity.
Qi J; Zhang J; Liu N; Zhao L; Xu B
Front Oncol; 2022; 12():779276. PubMed ID: 35311069
[TBL] [Abstract][Full Text] [Related]
2. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B
J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038
[TBL] [Abstract][Full Text] [Related]
3. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N
J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388
[TBL] [Abstract][Full Text] [Related]
4. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).
Ding XL; Su YG; Yu L; Bai ZL; Bai XH; Chen XZ; Yang X; Zhao R; He JX; Wang YY
World J Surg Oncol; 2022 Feb; 20(1):54. PubMed ID: 35220975
[TBL] [Abstract][Full Text] [Related]
6. Molecular subtypes, predictive markers and prognosis in small-cell lung carcinoma.
Zhu Y; Li S; Wang H; Ren W; Chi K; Wu J; Mao L; Huang X; Zhuo M; Lin D
J Clin Pathol; 2023 Sep; ():. PubMed ID: 37775262
[TBL] [Abstract][Full Text] [Related]
7. Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance.
Hwang S; Hong TH; Kim HK; Choi YS; Zo JI; Shim YM; Han J; Chan Ahn Y; Pyo H; Noh JM; Lee HY; Kim HJ; Park S; Ahn MJ; Park K; Lee SH; Choi YL; Kim J
Mod Pathol; 2023 Jul; 36(7):100184. PubMed ID: 37054974
[TBL] [Abstract][Full Text] [Related]
8. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
Chiang CL; Huang HC; Luo YH; Shen CI; Chao HS; Tseng YH; Chou TY; Schrump DS; Yeh YC; Chen YM
Lung Cancer; 2024 Feb; 188():107473. PubMed ID: 38232600
[TBL] [Abstract][Full Text] [Related]
10. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.
Kim G; Kim M; Nam EJ; Lee JY; Park E
Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832
[TBL] [Abstract][Full Text] [Related]
11. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.
Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T
Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573
[TBL] [Abstract][Full Text] [Related]
12. Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors.
Sato Y; Okamoto I; Kameyama H; Kudoh S; Saito H; Sanada M; Kudo N; Wakimoto J; Fujino K; Ikematsu Y; Tanaka K; Nishikawa A; Sakaguchi R; Ito T
Diagnostics (Basel); 2020 Nov; 10(11):. PubMed ID: 33202998
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtype expression and genomic profiling differ between surgically resected pure and combined small cell lung carcinoma.
Zhu Y; Li S; Wang H; Chi K; Ren W; Huang X; Zhuo M; Lin D
Hum Pathol; 2023 Nov; 141():118-129. PubMed ID: 37586462
[TBL] [Abstract][Full Text] [Related]
14. Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma.
Denize T; Meador CB; Rider AB; Ganci ML; Barth JL; Kem M; Mino-Kenudson M; Hung YP
Histopathology; 2023 Dec; 83(6):912-924. PubMed ID: 37644667
[TBL] [Abstract][Full Text] [Related]
15. Tumor-derived Vimentin as a novel biomarker for distinct subtypes predicting adjuvant chemotherapy resistance and T-cell-inflamed phenotype in small cell lung cancer.
Deng C; Wang Y; Fu F; Li D; Zheng Q; Jin Y; Li Y; Chen H; Zhang Y
MedComm (2020); 2023 Oct; 4(5):e370. PubMed ID: 37789961
[TBL] [Abstract][Full Text] [Related]
16. Molecular features and evolutionary trajectory of ASCL1
Zhang X; Wang H; Liu W; Xiao Z; Ma Z; Zhang Z; Gong W; Chen J; Liu Z
Br J Cancer; 2023 Mar; 128(5):748-759. PubMed ID: 36517551
[TBL] [Abstract][Full Text] [Related]
17. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD
Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245
[TBL] [Abstract][Full Text] [Related]
18. Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer.
Dora D; Rivard C; Yu H; Pickard SL; Laszlo V; Harko T; Megyesfalvi Z; Gerdan C; Dinya E; Hoetzenecker K; Hirsch FR; Lohinai Z; Dome B
Cancer Immunol Immunother; 2023 Mar; 72(3):561-578. PubMed ID: 35978199
[TBL] [Abstract][Full Text] [Related]
19. Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma.
Koh J; Kim H; Moon KC; Lee C; Lee K; Ryu HS; Jung KC; Jeon YK
Am J Surg Pathol; 2023 Feb; 47(2):183-193. PubMed ID: 36253891
[TBL] [Abstract][Full Text] [Related]
20. ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.
Miyakawa K; Miyashita N; Horie M; Terasaki Y; Tanaka H; Urushiyama H; Fukuda K; Okabe Y; Ishii T; Kuwahara N; Suzuki HI; Nagase T; Saito A
Cancer Sci; 2022 Nov; 113(11):3932-3946. PubMed ID: 35789143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
